Manufacturer
GlaxoSmithKline Manufacturing S.p.A
Contents
Remifentanil HCl
Indication
Analgesic agent during induction &/or maintenance of general anaesth during surgical procedures including cardiac surgery; continuation of analgesia into immediate post-op period, during transition to longer-acting analgesia. Provision of analgesia & sedation in mechanically ventilated intensive care patients.
Instruction
Adult General anaesth induction 0.5-1 mcg/kg/min w/ or w/o an initial bolus infusion of 1 mcg/kg over not <30 sec. Maintenance Dosage may be decreased individually & supplemental bolus infusion may be administered every 2-5 min. Spontaneously breathing anaesthetised patient w/ secured airway Initially 0.04 mcg/kg/min. Continuation into immediate post-op period Patient breathing spontaneously Initially, decrease infusion rate to 0.1 mcg/kg/min, may then be increased or decreased by not >0.025 mcg/kg/min every 5 min. Cardiac anaesth induction Initially 1 mcg/kg/min. Maintenance 0.5 mcg/kg. Intensive care patient Initially 0.1-0.15 mcg/kg/min, titrated in increments of 0.025 mcg/kg/min. Further increase in increments of 0.025 mcg/kg/min if additional analgesia is required. Additional analgesia for ventilated patient undergoing stimulation procedures Maintain 0.1 mcg/kg/min for at least 5 min prior to procedure, may be adjusted every 2-5 min. Max: 0.75 mcg/kg/min.
Drug interaction
Decreased amount or dose of inhaled & IV anaesth & benzodiazepines required for anaesth. Exacerbated CV effects eg, hypotension, bradycardia w/ cardiac depressants drugs eg, β-blockers & Ca-channel blockers. Limit dosage & duration of use w/ benzodiazepines & opioids.
Malaysia
